National Institute on Drug Abuse; Notice of Closed Meetings, 27622 [2018-12674]
Download as PDF
<![CDATA[
27622
Federal Register / Vol. 83, No. 114 / Wednesday, June 13, 2018 / Notices
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Natalia Komissarova,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5207,
MSC 7846, Bethesda, MD 20892, 301–435–
1206, komissar@mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Immune Mechanism: Activation,
Regulation and Tolerance.
Date: July 11, 2018.
Time: 12:30 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Patrick K. Lai, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2215,
MSC 7812, Bethesda, MD 20892, 301–435–
1052, laip@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: June 7, 2018.
David D. Clary,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–12671 Filed 6–12–18; 8:45 am]
BILLING CODE 4140–01–P
Place: Hilton Garden Inn Bethesda, 7301
Waverly Street, Bethesda, MD 20814.
Contact Person: Ivan K. Navarro, Ph.D.,
Scientific Review Officer, Office of
Extramural Policy and Review, Division of
Extramural Research, National Institute on
Drug Abuse, NIH, DHHS, 6001 Executive
Boulevard, Room 4242, MSC 9550, Bethesda,
MD 20892, 301–827–5833, ivan.navarro@
nih.gov.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel;
Development of Medications to Prevent and
Treat Opioid Use Disorders and Overdose
(UG3/UH3 (Clinical Trials Optional).
Date: August 16, 2018.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate
cooperative agreement applications.
Place: Bethesda North Marriott Hotel &
Conference Center, 5701 Marinelli Road,
Bethesda, MD 20852.
Contact Person: Ivan K. Navarro, Ph.D.,
Scientific Review Officer, Office of
Extramural Policy and Review, Division of
Extramural Research, National Institute on
Drug Abuse, NIH, DHHS, 6001 Executive
Boulevard, Room 4242, MSC 9550, Bethesda,
MD 20892, 301–827–5833, ivan.navarro@
nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos.: 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
Dated: June 7, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2018–12674 Filed 6–12–18; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institute on Drug Abuse;
Notice of Closed Meetings
amozie on DSK3GDR082PROD with NOTICES1
National Institutes of Health
National Institutes of Health
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel; SEP for
Medications Development.
Date: June 27, 2018.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
VerDate Sep<11>2014
18:01 Jun 12, 2018
Jkt 244001
Request for Data and Information on
Technologies Used To Detect and
Measure Botulinum Neurotoxin
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice.
The National Toxicology
Program (NTP) Interagency Center for
the Evaluation of Alternative
Toxicological Methods (NICEATM)
requests available data and information
on approaches and/or technologies
currently used to detect and measure
botulinum neurotoxin (BoNT).
Submitted information will be used to
assess the state of the science and
determine technical needs for nonanimal test methods that are used to
detect the presence of BoNT and
measure potency of BoNT preparations.
DATES: Receipt of information: Deadline
is July 11, 2018.
SUMMARY:
PO 00000
Frm 00085
Fmt 4703
Sfmt 4703
Data and information
should be submitted electronically to
niceatm@niehs.nih.gov.
FOR FURTHER INFORMATION CONTACT: Dr.
Warren Casey, Director, NICEATM;
email: warren.casey@nih.gov; telephone:
(984) 287–3118.
SUPPLEMENTARY INFORMATION:
Background: NICEATM fosters the
evaluation and promotion of alternative
test methods for regulatory use. As part
of this activity, NICEATM supports
efforts to develop, validate, and
implement alternative approaches for
biologics tests, including those used to
detect the presence of BoNT and
measure potency of BoNT preparations.
Tests to detect and measure BoNT are
required by multiple federal agencies for
regulatory and other decision contexts.
Currently, the standard test for these
endpoints is a mouse lethality assay that
can use large numbers of animals.
Request for Information: NICEATM
requests available data and information
on approaches and/or technologies
currently used to detect the presence of
BoNT and measure potency of BoNT
preparations. Respondents should
provide information on any activities
relevant to the development or
validation of alternatives to in vivo test
methods currently used by federal
agencies for regulatory and other
decision contexts. NICEATM also
requests available data from in vivo
BoNT tests used for similar applications
as the proposed alternative, such as
distinguishing between BoNT serotypes
in biological matrix samples or
measuring the potency of therapeutic
BoNT preparations.
Respondents to this request for
information should include their name,
affiliation (if applicable), mailing
address, telephone, email, and
sponsoring organization (if any) with
their communications. The deadline for
receipt of the requested information is
July 11, 2018. Responses to this notice
will be posted at: https://ntp.niehs.
nih.gov/go/bont. Persons submitting
responses will be identified on the web
page by name and affiliation or
sponsoring organization, if applicable.
Responses to this request are
voluntary. No proprietary, classified,
confidential, or sensitive information
should be included in responses. This
request for information is for planning
purposes only and is not a solicitation
for applications or an obligation on the
part of the U.S. Government to provide
support for any ideas identified in
response to the request. Please note that
the U.S. Government will not pay for
the preparation of any information
ADDRESSES:
E:\FR\FM\13JNN1.SGM
13JNN1
]]>Agencies
[Federal Register Volume 83, Number 114 (Wednesday, June 13, 2018)]
[Notices]
[Page 27622]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-12674]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; SEP for Medications Development.
Date: June 27, 2018.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Hilton Garden Inn Bethesda, 7301 Waverly Street,
Bethesda, MD 20814.
Contact Person: Ivan K. Navarro, Ph.D., Scientific Review
Officer, Office of Extramural Policy and Review, Division of
Extramural Research, National Institute on Drug Abuse, NIH, DHHS,
6001 Executive Boulevard, Room 4242, MSC 9550, Bethesda, MD 20892,
301-827-5833, [email protected].
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Development of Medications to Prevent and Treat
Opioid Use Disorders and Overdose (UG3/UH3 (Clinical Trials
Optional).
Date: August 16, 2018.
Time: 8:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate cooperative agreement
applications.
Place: Bethesda North Marriott Hotel & Conference Center, 5701
Marinelli Road, Bethesda, MD 20852.
Contact Person: Ivan K. Navarro, Ph.D., Scientific Review
Officer, Office of Extramural Policy and Review, Division of
Extramural Research, National Institute on Drug Abuse, NIH, DHHS,
6001 Executive Boulevard, Room 4242, MSC 9550, Bethesda, MD 20892,
301-827-5833, [email protected].
(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug
Abuse and Addiction Research Programs, National Institutes of
Health, HHS)
Dated: June 7, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-12674 Filed 6-12-18; 8:45 am]
BILLING CODE 4140-01-P
